Turmoil in emerging markets is the culprit of choice for the U.S. stock market�� sputtering start in 2014. Traders worry about slowing growth, fragile currencies and political unrest in Turkey, Ukraine and elsewhere. Never mind that U.S. economic indicators are green and that Europe again has a pulse. It doesn�� take much in this inter颅related world to end what one commentator recently called ��liss��in financial markets.
See Also: The World�� Most Vulnerable Emerging Markets
I worry that emerging-markets stocks, which got off to a terrible start this year, will continue to sag. However, if you hop to the developing world�� bond markets, the vibes change. With bonds, the swings and the emotions aren�� as wild. You should do okay this year, certainly better than in 2013, when the average emerging-markets bond mutual fund lost 7.3%, mostly because of appreciation in the dollar. The typical emerging-markets bond fund yields 5% to 6%, and the income is generally secure. Few countries are close to reneging on their obligations. And keep in mind that emerging-markets debt isn�� synonymous with government bonds. Scores of vibrant, investment-grade, multinational firms that focus on oil, mining, agribusiness, brewing and construction are based in the developing world. These companies pay about two percentage points more to borrow than similarly rated U.S. and European firms.
Top 5 Managed Healthcare Stocks To Watch Right Now: ViroPharma Incorporated(VPHM)
ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.
Advisors' Opinion:- [By George Budwell]
Shire plc (NASDAQ: SHPG ) is in the process of buying orphan drug-specialist ViroPharma (NASDAQ: VPHM ) for $4.2 billion, strengthening Shire's already robust commercial drug portfolio for rare diseases. The deal is expected to be finalized no later than Jan. 9, after Shire extended its tender offer to acquire all outstanding ViroPharma shares last week.
- [By Sean Williams]
What: Shares of ViroPharma (NASDAQ: VPHM ) , a biotechnology company specializing in treating rare diseases, rose as much as 14% after a report from Reuters noted preliminary buyout interest in the company.
Top 5 Income Stocks To Invest In Right Now: Repligen Corporation(RGEN)
Repligen Corporation engages in the manufacture and supply of biologic products used to manufacture biologic drugs. The company offers commercial bioprocessing products based on protein A and IFG-1 growth factors; and pre-packed chromatography columns under the Opus brand, which are used in the production of monoclonal antibodies and other biopharmaceutical products. It also develops SecreFlo, a synthetic human hormone that has completed a Phase III clinical trial and is to be used in combination with magnetic resonance imaging to improve the detection of pancreatic abnormalities in patients with pancreatitis; RG3039, which is in Phase I study for the treatment of patients with spinal muscular atrophy; and RG2833, a class I histone deacetylase inhibitor that is in Phase I study for the treatment of patients with Friedreich?s ataxia. In addition, the company licenses its biologics intellectual property to Bristol-Myers Squibb Company. Repligen Corporation sells its bioproc essing products to life science companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers through its direct sales force, partners, and distributors in certain foreign markets. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (NASDAQ: RGEN ) has earned a coveted five-star ranking.
- [By CRWE]
Repligen Corporation (NASDAQ:RGEN) reported that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston.
- [By Maxx Chatsko]
Any company that creates products and relies on other companies to use and distribute them will inevitably forge strong relationships with its customers. It's an important thing to look into when investing, yet easy to overlook. Investors should know whether customers are reliable, which are leaned on the most, and if the company they own is too dependent on any customer (or a select few). Bioprocessing product company Repligen (NASDAQ: RGEN ) may make consumables that are the lifeline of the biotech industry, but its customer relationships are absolutely critical for smooth operations. Let's look at how the company interacts with the Life Sciences division of General Electric (NYSE: GE ) , EMD Millipore from Merck (NYSE: MRK ) , and Sigma-Aldrich (NASDAQ: SIAL ) -- the three most important customers.
Top 5 Income Stocks To Invest In Right Now: Universal Technical Institute Inc(UTI)
Universal Technical Institute, Inc. engages in the provision of postsecondary education for students seeking careers as professional automotive, diesel, collision repair, motorcycle, and marine technicians in the United States. It offers undergraduate degree, diploma, and certificate programs through its campuses under various brands, including Universal Technical Institute, Motorcycle Mechanics Institute and Marine Mechanics Institute, and NASCAR Technical Institute. The company also provides manufacturer-specific training programs comprising student paid electives at its campuses and manufacturer or dealer sponsored training at certain campuses and dedicated training centers. Universal Technical Institute, Inc. was founded in 1965 and is headquartered in Scottsdale, Arizona.
Advisors' Opinion:- [By Laura Brodbeck]
Tuesday
Earnings Expected From: Bank of Montreal (NYSE: BMO), United Natural Foods, Inc. (NASDAQ: UNFI), OmniVision Technology, Inc. (NASDAQ: OVTI), Universal Technical Institute, Inc. (NYSE: UTI) Economic Releases Expected: Chinese HSBC Services PMI, Australian GDP, Brazilian GDP, eurozone PPI, British construction PMI.Wednesday
Top 5 Income Stocks To Invest In Right Now: Capital City Bank Group(CCBG)
Capital City Bank Group, Inc. operates as the bank holding company for Capital City Bank that provides commercial and retail banking products and services. Its deposit products include negotiable order of withdrawal accounts, money market accounts, checking and savings accounts, and time deposits. The company offers financing for commercial business properties, equipment, inventories, and accounts receivable, as well as commercial leasing and letters of credit; commercial and residential real estate lending; retail credit products, including personal loans, automobile loans, boat/recreational vehicle loans, home equity loans, and credit card programs; and tax-exempt loans, lines of credit, and term loans. It also provides treasury management services, merchant credit card transaction processing services, automated teller machines (ATMs), debit/credit cards, night deposit services, safe deposit facilities, PC/Internet banking, and mobile banking services. In addition, the c ompany offers asset management, trust, mortgage banking, merchant services, and data processing services, as well as securities brokerage services, including U.S. government bonds, tax-free municipal bonds, stocks, mutual funds, unit investment trusts, annuities, life insurance, and long-term health care. It serves individuals, corporations, and other business clients, including commercial developers and investors, residential builders and developers, community developers, state and local governments, public schools and colleges, charities, and membership and not-for-profit associations. As of January 27, 2012, the company operated 70 banking offices and 79 ATMs in Florida, Georgia, and Alabama. Capital City Bank Group, Inc. was founded in 1895 and is headquartered in Tallahassee, Florida.
Advisors' Opinion:- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
CTBI is trading at a premium to all four valuations above. The stock is trading at a 53.5% premium to its calculated fair value of $29.43. CTBI did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
CTBI earned one Star in this section for 1.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The company has paid a cash dividend to shareholders every year since 1988 and has increased its dividend payments for 33 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
The negative NPV MMA Diff. means that on a NPV basis the dividend earnings from an investment in CTBI would be less than a similar amount invested in MMA earning a 20-year average rate of 3.41%. If CTBI grows its dividend at 1.5% per year, it will never equal a MMA yielding an estimated 20-year average rate of 3.41%.
Memberships and Peers: CTBI is, a member of the Broad Dividend Achieve
No comments:
Post a Comment